BioCentury
ARTICLE | Clinical News

Venclexta venetoclax: Phase Ib data

May 23, 2016 7:00 AM UTC

Data from 34 evaluable treatment-naive AML patients ages >65 in an open-label, dose-escalation, international Phase Ib trial showed that once-daily oral Venclexta plus decitabine or azacitidine led to...